论文部分内容阅读
目的 :探索医药制造业创新能力在空间分布中的规律及价值。方法 :基于空间计量分析原理,选取2010年的研发人员全时当量和研发经费内部支出作为解释变量,2010-2013年的新产品销售收入作为被解释变量,运用普通计量回归模型(OLS)、空间计量回归模型(空间滞后模型和空间误差模型),应用Geo Da和R软件,对中国医药制造业的研发投入与产出关系进行了研究。结果 :医药制造业创新投入产出滞后1年,医药制造业各区域创新能力的全局Moran’s I系数有统计学意义;区域显示上海、江苏存在较高的创新能力和集聚效应,安徽、福建、黑龙江等空间相关性不强。结论 :针对不同的区域选择性地加强研发经费的投入,充分发挥高创新能力省区的知识溢出效应,促进技术创新能力不足的省区发展,从而提高我国医药制造业创新能力。
Objective: To explore the law and value of the innovation ability of pharmaceutical manufacturing industry in spatial distribution. Methods: Based on the principle of spatial econometrics, the full-time R & D staff and the internal expenditure of R & D expenditures in 2010 were selected as explanatory variables. The sales revenue of new products in 2010-2013 was interpreted as explanatory variables. OLS and OLS Econometric regression model (spatial lag model and spatial error model) is applied to study the relationship between R & D input and output of Chinese pharmaceutical industry using Geo Da and R software. Results: The innovation and input-output of pharmaceutical manufacturing lagged for one year. The global Moran’s I coefficient of innovation ability in each region of pharmaceutical manufacturing was statistically significant. The regions showed that Shanghai and Jiangsu had higher innovation ability and agglomeration effect. Anhui, Fujian and Heilongjiang Spatial correlation is not strong. CONCLUSIONS: In view of the different regions selectively investing in research and development funds, giving full play to the knowledge spillover effect of highly innovative provinces and regions and promoting the development of provinces and autonomous regions with insufficient technological innovation capacity, thereby enhancing the innovation capability of pharmaceutical manufacturing in our country.